Home| Journals | Statistics Online Expert | About Us | Contact Us

    About this Journal  | Table of Contents

[Abstract] [PDF] [HTML] [Linked References]

International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109

Volume 11, Issue 2, June 2014 pp 155-158

Research Article

Study on thrombocytopenia occurring in P vivax malaria at a tertiary centre in Southern India

Sanju Daniel John*, Peter George**

*Resident, **Professor, Department of Medicine, Father Muller Medical College, Father Muller Road, Mangalore -575002,  Karnataka, INDIA.

Academic Editor : Dr. Aher K.R.



Background: Malaria caused by P vivax is endemic to most of the tropical nations and are associated with various hematological abnormalities. Complications were more common among P falciparum infections as compared to P vivax infections. Recent literature suggests more severe forms of P vivax infections including cases with severe thrombocytopenia. Objectives: To study the occurrence of thrombocytopenia in P vivax malaria at a tertiary centre in Southern India. Materials and Methods: This retrospective cohort study was done among in-patients with P vivax malaria at a tertiary care center in Southern India over a period of 18 months from October 2012. A total of 200 patients with positive peripheral smear for P vivax malaria and negative for HRP-2 test were included in the study. The thrombocytopenia was graded as per the protocol and results were analyzed by frequency, percentage, mean, standard deviation and chi-square tests. Results: among the 200 patients males (74.5%) were affected than females. Mean platelet count at admission was 85,277.78 /cmm. We observed grades of thrombocytopenia were grade -1 in 16.5%, grade -2 in 28.5%, grade -3 in 36.5% and grade -4 in 16.5% of these patients. Complications like ARDS (1%) and acute renal failure (1%) were seen in patients with severe thrombocytopenia. Conclusions: In this study, we found severe thrombocytopenia to occur in P vivax mono-infection. We felt P vivax should no longer be considered benign and thrombocytopenia could be an early feature of P vivax mono-infection.